 |
|
| Blog results | Results 1 - 10 of about 1,291 for neuroendocrine tumor search results. (0.29 seconds) |
| Sorted by relevance Sort by date |
| Related Blogs: | My journey thru Neuroendocrine Carcinoma Cancer (Carcinoid) Hell ... - http://www.renalcarcinoid.com/ | |
| 8 Dec 2009 by "Renal Carincoid Guy" You will have to look through these summaries and click the link which may be the data you are looking for (I deleted a number of the search entry results to make this easier: My journey thru Neuroendocrine Carcinoma Cancer Hell ... My journey thru Neuroendocrine Carcinoma... - http://www.renalcarcinoid.com/ [ More results from My journey thru Neuroendocrine Carcinoma... ] |
| 1 Nov 2009 by Cristina Research findings are pessimistic, the final results of this type of cancer are the same, regardless of age or sex of sick person or location of the tumor. Although neuroendocrine carcinoma of the colon depends on the stage where the tumor, generally patients in stages 1 and 2 of the disease do not suffer from this type of colon cancer (neuroendocrine). In most cases where the tumor is in stage 3 or 4, is very difficult to determine if it is ... Search This Blog. Loading. ... About cancer - A to Z - http://a-z-cancer.blogspot.com/ |
| 2 Oct 2009 by mjames Among patients with advanced neuroendocrine tumors of the midgut, treatment with Sandostatin® LAR Depot (octreotide acetate for injectable suspension) appears to significantly delay cancer progression. The results of this Phase III ... CancerConsultants - http://www.cancerconsultants.com/ |
| 10 hours ago by ML Patients who took Afinitor monotherapy remained progression-free for 9.7 months and nearly 60% of patients experienced a decrease in tumor size.Furthermore, the results of RADIANT-1 were evaluated to explore biomarkers that may help identify the patients most likely to benefit from treatment with Afinitor. An analysis of the study data showed that patients who demonstrated an early response on chromogranin A (CgA) and neuron-specific enolase (NSE) ... Google. Safe Search ... Cancer Treatment - http://cancertreatments.typepad.com/cancer_treatment/ |
| 5 hours ago by admin Patients who took Afinitor monotherapy remained progression-free for 9.7 months and nearly 60% of patients experienced a decrease in tumor size.Furthermore, the results of RADIANT-1 were evaluated to explore biomarkers that may help ... Cancer Treatment Blog - http://www.cancertreatmentblog.com/ |
| 5 Oct 2009 These data were presented on October 2, 2009, at the North American Neuroendocrine Tumor Society (NANETS) 2009 Neuroendocrine Tumor Symposium in Charlotte, North Carolina. Azedra (UltratraceTM iobenguane I 131) is Molecular Insight's lead ... “These results at one year after therapy demonstrate that Azedra therapy may potentially benefit many patients who have metastatic pheochromocytoma or paraganglioma.” Data reported today provide long-term confirmation of ... Search: ... Drugs.com - Clinical Trials - http://www.drugs.com/clinical_trials.html [ More results from Drugs.com - Clinical Trials ] |
| 9 Oct 2008 Surgery remains the mainstay of treatment for patients with potentially curable tumors, and adequate selection is paramount in order to optimize treatment results. Regarding systemic therapy, patients with well-differentiated tumors or ... American Journal of Nephrology : Last 20 articles - http://content.karger.com/ [ More results from American Journal of Nephrology : Last 20 articles ] |
| 9 Oct 2009 by Caring for Carcinoid Foundation 1) Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group ... 2) Pasireotide LAR In Patients With Metastatic Carcinoid Tumors: Interim Safety Results From A Randomized, Multicenter Phase I Study. Edward Wolin, Larry Kvols, Shereen Ezzat, Walter Kocha, Eric Van Cutsem, Ulrike Schönherr and Abderrahim Fandi. ... CFCF Research Updates - http://cfcfresearch.blogspot.com/ [ More results from CFCF Research Updates ] |
| 9 Dec 2009 In addition, results from the Phase II RADIANT-1 study presented earlier this year at the 11th World Congress on Gastrointestinal Cancer showed that 84% of patients with advanced pancreatic neuroendocrine tumors (pNET) treated with ... PharmaNews.eu - http://www.pharmanews.eu/component/content/frontpage - References [ More results from PharmaNews.eu ] |
| 27 Nov 2009 by Bugalho, MJ, Domingues, R., Borges, A. Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor arising from "C" cells of the thyroid; it is a RET associated cancer that can be sporadic or familial in origin. Advances in understanding the ... Patient and Results. A 55-year- old man with locally advanced MTC, without germinal and/or somatic RET mutations, was started on sunitinib (50 mg/day for 28 days, followed by 14 days of no treatment). At the time of writing, he had received four consecutive cycles. ... The Oncologist current issue - http://theoncologist.alphamedpress.org/ |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
